AKT2 and ulcerative colitis: Furthermore, miRNA-200b treatment in a mouse model of ulcerative colitis-related colorectal cancer was shown to attenuate inflammatory responses through the blockade of the AKT2-mediated NF-κB/IL-6 signaling pathway, which is considered to be the molecular mechanism of the inhibition of inflammation [46].